News Update
2024-07-04
- Developed a multispecific antibody platform technology that can target multiple antigens simultaneously with a single molecule, showcasing its own drug development capabilities.
- Currently exploring new pipeline of T cell engagers using the multispecific antibody platform technology, with ongoing research.
July 04, 2024 — ROCKVILLE, MD: NeoImmuneTech, Inc. (NIT), a global leader in T-cell-based immunotherapy, today announced that it has developed and secured a platform technology capable of creating various forms of multispecific antibodies, including bispecific antibodies. NIT has filed a Patent Cooperation Treaty (PCT) application for this technology.
The patent, titled "Heterodimeric Fc Molecules and Uses Thereof," includes the Fc protein sequences of antibodies that incorporate mutation sequences to form heterodimers. This achievement is the result of a collaboration between NeoImmuneTech and Pohang University of Science and Technology (POSTECH) since 2022.
The heterodimeric Fc is crucial for developing multispecific antibodies, allowing simultaneous targeting of multiple antigens, which traditional monoclonal antibodies cannot achieve.
NeoImmuneTech is already expanding its development pipeline using this technology. For example, this technology is integral to NT30, a new T cell engager in NeoImmuneTech’s pipeline.
Dr. Luke Oh, Ph.D., President of NeoImmuneTech, Inc. said: "In parallel of the accelerated clinical development of our asset NT-I7, our team continues to advance antibody science. We plan to actively protect our platform technology in major markets worldwide, including the US and Europe, to expand our proprietary development pipeline."